City

Clinical trials near Bialystok, Poland

Active studies with a listed research site in Bialystok, Poland.

15active studies

10recruiting now

27countries represented

82largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Type 2 DiabetesCondition

LY3457263, PlaceboTreatment

Canada, Germany60 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT06897475See eligibility →

Recruiting nowPhase 3

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

Overweight, ObesityCondition

Semaglutide, PlaceboTreatment

Belgium, Bulgaria62 locations

Novo Nordisk A/SSponsor

Updated 2026-08-18 · NCT07770841See eligibility →

Recruiting nowPhase 3

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, Bulgaria81 locations

Novo Nordisk A/SSponsor

Updated 2026-08-17 · NCT07509307See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil57 locations

AmgenSponsor

Updated 2026-08-14 · NCT07226765See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

UBT251, UBT251 PlaceboTreatment

Australia, Germany70 locations

Novo Nordisk A/SSponsor

Updated 2026-08-10 · NCT07668388See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

NNC0662-0419, SemaglutideTreatment

Croatia, Hungary63 locations

Novo Nordisk A/SSponsor

Updated 2026-08-10 · NCT07415954See eligibility →

Recruiting nowPhase 3

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity, Knee Osteoarthritis (OA)Condition

NNC0487-0111, Placebo (matched to NNC0487-0111 )Treatment

Australia, Bulgaria82 locations

Novo Nordisk A/SSponsor

Updated 2026-07-09 · NCT07481630See eligibility →

Recruiting nowNot applicable

The Bialystok Bariatric Surgery Study

Obesity, Diabetes MellitusCondition

Bariatric surgeryTreatment

Poland1 locations

Medical University of BialystokSponsor

Updated 2026-04-14 · NCT04634591See eligibility →

Recruiting nowNot applicable

Polish Registry of Diabetes (PolReD)

Diabetes, ObesityCondition

Observational study - registryTreatment

Poland1 locations

Medical University of BialystokSponsor

Updated 2025-03-26 · NCT04657367See eligibility →

Recruiting nowNot applicable

Genetics of the Acute Response to Oral Semaglutide

PreDiabetes, Prediabetic StateCondition

Semaglutide PillTreatment

Poland1 locations

Medical University of BialystokSponsor

Updated 2025-03-26 · NCT05340868See eligibility →

Invitation onlyNot applicable

Białystok PLUS - Polish Longitudinal University Study

Cardiovascular Diseases, DiabetesCondition

Discovering novel risk factors.Treatment

Poland1 locations

Medical University of BialystokSponsor

Updated 2023-03-15 · NCT03197363See eligibility →

Active, not recruitingPhase 3

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

Obesity, OverweightCondition

Cagrilintide, PlaceboTreatment

Argentina, Australia40 locations

Novo Nordisk A/SSponsor

Updated 2026-08-06 · NCT07220642See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Obesity, OverweightCondition

Retatrutide, PlaceboTreatment

Argentina, Canada40 locations

Eli Lilly and CompanySponsor

Updated 2026-07-23 · NCT07035093See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

ObesityCondition

Retatrutide, TirzepatideTreatment

Argentina, Germany65 locations

Eli Lilly and CompanySponsor

Updated 2026-07-20 · NCT06662383See eligibility →

Active, not recruitingPhase 2

A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

Type 2 Diabetes MellitusCondition

RO7795081, SemaglutideTreatment

Hungary, Poland50 locations

Hoffmann-La RocheSponsor

Updated 2026-07-07 · NCT07112872See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Bialystok, Poland

Current studies

Related cities